A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lanreotide (Primary) ; Yttrium-90 (Primary)
Indications Carcinoid tumour; Gastrointestinal cancer; Neuroendocrine carcinoma; Pancreatic cancer
Focus Adverse reactions

05 Jul 2022 Status changed from active, no longer recruiting to discontinued (due to slow accrual)
06 Jun 2022 Planned End Date changed from 31 Dec 2022 to 1 Mar 2023.
04 Apr 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Nov 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com